Johnson & Johnson Innovation is expanding its innovation strategy with the opening of a new bioincubator in Europe, designed to identify and nurture early-stage companies.
The initiative called JLINX, will be based at the Janssen campus in Beerse, Belgium, and aims to catalyse innovation by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem.
JLINX will be located in a dedicated facility and will be managed by a third party, Bioqube Ventures, which will provide independent oversight for venture funding and company selection.
